According to Eagle Pharmaceuticals
's latest financial reports the company has a price-to-book ratio of 0.1761.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 0.2695 | -83.46% |
2022-12-31 | 1.63 | -56.29% |
2021-12-31 | 3.73 | 14.24% |
2020-12-31 | 3.26 | -28.62% |
2019-12-31 | 4.57 | 31.07% |
2018-12-31 | 3.49 | -21.63% |
2017-12-31 | 4.45 | -45.2% |
2016-12-31 | 8.12 | -47.09% |
2015-12-31 | 15.3 | 96.86% |
2014-12-31 | 7.80 | |
2013-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.99 | 2,735.75% | ๐บ๐ธ USA |
Novartis NVS | 5.17 | 2,835.01% | ๐จ๐ญ Switzerland |
Eli Lilly LLY | 60.1 | 34,008.41% | ๐บ๐ธ USA |
Amgen AMGN | 32.2 | 18,158.79% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 4.93 | 2,700.02% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 5.51 | 3,028.74% | ๐ฌ๐ง UK |
Teva Pharmaceutical Industries TEVA | 2.54 | 1,341.12% | ๐ฎ๐ฑ Israel |